STN Stock Analysis: Stantec | NYSE
Engineering & Construction | NYSE, USA | Market Cap: 8.304m USD | 12M Return: -31% | CA85472N1096 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.6M
EPS Trend: 98.0%
Qual. Beats: 0
Rev. Trend: 88.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stantec Inc. is a Canadian professional services firm that provides engineering, architecture, environmental, and project management services to both public and private clients across Canada, the United States, and international markets. Founded in 1954 and headquartered in Edmonton, the company offers a broad range of capabilities spanning infrastructure planning and design, water resource management, sustainable building solutions, energy and resources consulting, and decommissioning and remediation services. Its client base includes government departments, local authorities, utility companies, and private-sector organizations, with service lines covering transportation, buildings, environmental sciences, geotechnical work, and mechanical, electrical, and plumbing (MEP) engineering.
The company, formerly known as Stanley Technology Group Inc. until its 1998 rebranding, trades on the NYSE under the ticker STN and is classified within the Industrials sector, specifically in the Research & Consulting Services sub-industry. As an engineering and consulting firm, Stantec operates on a project-based, fee-for-service revenue model, which is typical of the professional services industry and often correlates demand with capital expenditure cycles in infrastructure, construction, and environmental remediation.
- US IIJA funding boosts infrastructure consulting backlog
- Water infrastructure demand surges with EPA mandates
- Acquisition pipeline fuels double-digit organic growth target
| Net Income: 505.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.19 > 1.0 |
| NWC/Revenue: 12.47% < 20% (prev 11.09%; Δ 1.38% < -1%) |
| CFO/TA 0.09 > 3% & CFO 744.2m > Net Income 505.2m |
| Net Debt (3.08b) to EBITDA (1.16b): 2.65 < 3 |
| Current Ratio: 1.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.6m) vs 12m ago -0.44% < -2% |
| Gross Margin: 43.27% > 18% (prev 42.20%; Δ 1.08% > 0.5%) |
| Asset Turnover: 106.7% > 50% (prev 104.1%; Δ 2.64% > 0%) |
| Interest Coverage Ratio: 7.09 > 6 (EBIT TTM 777.5m / Interest Expense TTM 109.6m) |
| A: 0.12 (Total Current Assets 3.02b - Total Current Liabilities 2.01b) / Total Assets 8.23b |
| B: 0.22 (Retained Earnings 1.80b / Total Assets 8.23b) |
| C: 0.10 (EBIT TTM 777.5m / Avg Total Assets 7.60b) |
| D: 0.70 (Book Value of Equity 3.39b / Total Liabilities 4.83b) |
| Altman-Z'' = 2.94 = A |
| DSRI: 0.59 (Receivables 1.44b/2.19b, Revenue 8.11b/7.26b) |
| GMI: 0.98 (GM 42.20% / 43.27%) |
| AQI: 1.02 (AQ_t 0.53 / AQ_t-1 0.52) |
| SGI: 1.12 (Revenue 8.11b / 7.26b) |
| TATA: -0.03 (NI 505.2m - CFO 744.2m) / TA 8.23b) |
| Beneish M = -3.29 (Cap -4..+1) = AA |
As of August 24, 2026, the stock is trading at USD 74.07 with a total of 198,773 shares traded. Over the past week, the price has changed by +0.50%, over one month by +8.53%, over three months by -2.51% and over the past year by -30.96%.
Current recommended Stop Loss: 70.40 (which is 5% or 1.8 ATR below the current price).
Stantec has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy STN.
- StrongBuy: 3
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 94.3 | 27.3% |
Market Cap CAD = 11.4b (8.30b USD * 1.3778 USD.CAD)
P/E Trailing = 23.454
P/E Forward = 16.4204
P/S = 1.2176
P/B = 3.4362
P/EG = 1.3846
Revenue TTM = 8.11b CAD
EBIT TTM = 777.5m CAD
EBITDA TTM = 1.16b CAD
Long Term Debt = 1.53b CAD (from longTermDebt, last fiscal year)
Short Term Debt = 261.8m CAD (from shortTermDebt, last quarter)
Debt = 3.45b CAD (from shortLongTermDebtTotal, last quarter) + Leases 727.7m
Net Debt = 3.08b CAD (calculated: Debt 3.45b - CCE 377.3m)
Enterprise Value = 14.5b CAD (11.4b + Debt 3.45b - CCE 377.3m)
Interest Coverage Ratio = 7.09 (Ebit TTM 777.5m / Interest Expense TTM 109.6m)
EV/FCF = 21.80x (Enterprise Value 14.5b / FCF TTM 665.9m)
FCF Yield = 4.59% (FCF TTM 665.9m / Enterprise Value 14.5b)
FCF Margin = 8.21% (FCF TTM 665.9m / Revenue TTM 8.11b)
Net Margin = 6.23% (Net Income TTM 505.2m / Revenue TTM 8.11b)
Gross Margin = 43.27% ((Revenue TTM 8.11b - Cost of Revenue TTM 4.60b) / Revenue TTM)
Gross Margin QoQ = 54.52% (prev 39.62%)
Tobins Q-Ratio = 1.77 (Enterprise Value 14.5b / Total Assets 8.23b)
Interest Expense / Debt = 3.17% (Interest Expense 109.6m / Debt 3.45b)
Taxrate = 24.36% (162.7m / 667.9m)
NOPAT = 588.1m (EBIT 777.5m * (1 - 24.36%))
Current Ratio = 1.50 (Total Current Assets 3.02b / Total Current Liabilities 2.01b)
Debt / Equity = 1.02 (Debt 3.45b / totalStockholderEquity, last quarter 3.39b)
Debt / EBITDA = 2.65 (Net Debt 3.08b / EBITDA 1.16b)
Debt / FCF = 4.62 (Net Debt 3.08b / FCF TTM 665.9m)
Total Stockholder Equity = 3.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.65% (Net Income 505.2m / Total Assets 8.23b)
RoE = 15.26% (Net Income TTM 505.2m / Total Stockholder Equity 3.31b)
RoCE = 16.07% (EBIT 777.5m / Capital Employed (Equity 3.31b + L.T.Debt 1.53b))
RoIC = 9.64% (NOPAT 588.1m / Invested Capital 6.10b)
WACC = 6.41% (E(11.4b)/V(14.9b) * Re(7.62%) + D(3.45b)/V(14.9b) * Rd(3.17%) * (1-Tc(0.24)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -52.22 | Cagr: -0.20%
[DCF] Terminal Value 75.82% ; FCFF base≈658.4m ; Y1≈677.1m ; Y5≈752.3m
[DCF] Fair Price = 76.20 (EV 11.6b - Net Debt 3.08b = Equity 8.56b / Shares 112.4m; r=8.35% [WACC [floored]]; 5y FCF grow 2.91% → 2.50% )
EPS Correlation: 98.05 | EPS CAGR: 17.67% | SUE: 0.24 | # QB: 0
Revenue Correlation: 88.64 | Revenue CAGR: 18.54% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.78 | Chg30d=-1.67% | Revisions=-12% | Analysts=10
EPS current Year (2026-12-31): EPS=6.21 | Chg30d=+0.26% | Revisions=-44% | GrowthEPS=+17.1% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=6.94 | Chg30d=+0.96% | Revisions=+0% | GrowthEPS=+11.8% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: -28% (up=5, down=10)